Dennis Mulroy - AnaptysBio Chief Officer
| ANAB Stock | USD 15.85 0.82 5.46% |
Insider
Dennis Mulroy is Chief Officer of AnaptysBio
| Age | 70 |
| Address | 10770 Wateridge Circle, San Diego, CA, United States, 92121-5801 |
| Phone | 858 362 6295 |
| Web | https://www.anaptysbio.com |
Latest Insider Transactions
Dennis Mulroy Latest Insider Activity
Tracking and analyzing the buying and selling activities of Dennis Mulroy against AnaptysBio stock is an integral part of due diligence when investing in AnaptysBio. Dennis Mulroy insider activity provides valuable insight into whether AnaptysBio is net buyers or sellers over its current business cycle. Note, AnaptysBio insiders must abide by specific rules, including filing SEC forms every time they buy or sell AnaptysBio'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Dennis Mulroy over three months ago Disposition of 10000 shares by Dennis Mulroy of AnaptysBio at 40.13 subject to Rule 16b-3 | ||
Dennis Mulroy over three months ago Disposition of 6000 shares by Dennis Mulroy of AnaptysBio subject to Rule 16b-3 |
AnaptysBio Management Efficiency
The company has return on total asset (ROA) of (0.1785) % which means that it has lost $0.1785 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6182) %, meaning that it created substantial loss on money invested by shareholders. AnaptysBio's management efficiency ratios could be used to measure how well AnaptysBio manages its routine affairs as well as how well it operates its assets and liabilities. As of January 18, 2025, Return On Tangible Assets is expected to decline to -0.34. In addition to that, Return On Capital Employed is expected to decline to -0.37. At present, AnaptysBio's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 11 M, whereas Total Assets are forecasted to decline to about 354.3 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Stephen MD | Kura Oncology | 53 | |
| Kevin Capps | Crinetics Pharmaceuticals | N/A | |
| Esq JD | Kura Oncology | 58 | |
| Pamela Cramer | Rhythm Pharmaceuticals | 49 | |
| Kirsten Flowers | Kura Oncology | 49 | |
| James Hassard | Crinetics Pharmaceuticals | 58 | |
| David Connolly | Rhythm Pharmaceuticals | N/A | |
| DPHIL DPhil | CytomX Therapeutics | 57 | |
| Hunter MBA | Rhythm Pharmaceuticals | 56 | |
| Chris MBA | Crinetics Pharmaceuticals | N/A | |
| Roger Bakale | Kura Oncology | N/A | |
| Jennifer Chien | Rhythm Pharmaceuticals | 49 | |
| Hoyoung MD | CytomX Therapeutics | 56 | |
| Adriana MBA | Crinetics Pharmaceuticals | N/A | |
| Joseph Shulman | Rhythm Pharmaceuticals | 49 | |
| Jeff Knight | Crinetics Pharmaceuticals | 54 | |
| Marc MD | Kura Oncology | 50 | |
| Christopher Ogden | CytomX Therapeutics | 41 | |
| Jamie Moore | CytomX Therapeutics | N/A | |
| Thomas Doyle | Kura Oncology | 54 | |
| MBA BS | CytomX Therapeutics | 46 | |
Management Performance
| Return On Equity | -1.62 | ||||
| Return On Asset | -0.18 |
AnaptysBio Leadership Team
Elected by the shareholders, the AnaptysBio's board of directors comprises two types of representatives: AnaptysBio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AnaptysBio. The board's role is to monitor AnaptysBio's management team and ensure that shareholders' interests are well served. AnaptysBio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AnaptysBio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Martin Dahl, Senior Research | ||
| Monique Silva, Senior Affairs | ||
| James MD, Advisor | ||
| Beth Mueller, Senior Resources | ||
| Priya Raina, Senior Operations | ||
| FAAD MBA, Chief Officer | ||
| Daniel Faga, Interim Director | ||
| MSc MBA, Advisory | ||
| Dennis Mulroy, Chief Officer | ||
| Douglas MBA, Senior CMC | ||
| Eric Loumeau, General Counsel | ||
| Benjamin Stone, Chief Officer | ||
| MSc MD, Senior Development |
AnaptysBio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AnaptysBio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.62 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (2.90) % | ||||
| Operating Margin | (0.76) % | ||||
| Current Valuation | 43.72 M | ||||
| Shares Outstanding | 30.43 M | ||||
| Shares Owned By Insiders | 1.73 % | ||||
| Shares Owned By Institutions | 98.27 % | ||||
| Number Of Shares Shorted | 7.33 M | ||||
| Price To Earning | 81.21 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.38) | Revenue Per Share | Quarterly Revenue Growth 8.047 | Return On Assets | Return On Equity |
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AnaptysBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if AnaptysBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.